Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional) | PAR-25-078 | NCI | This notice of funding opportunity (NOFO) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports… More | ||
| Co-infection and Cancer (R01 Clinical Trial Not Allowed) | PAR-25-082 | NCI | This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be… More |
||
| Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) | PAR-25-106 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use… More | ||
| Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) | PAR-25-254 | NCI | This Notice of Funding Funding Opportunity (NOFO) supports research on expectancy-generating factors and measures of their effects on expectancies and subsequent cancer symptom management outcomes;… More | ||
| Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) | PAR-25-094 | NCI | Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to focus on the impacts of climate change across the cancer control continuum (R01 Clinical Trial… More | ||
| Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) | PAR-25-152 | NCI | Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to focus on the impacts of climate change across the cancer control continuum (R01 Clinical Trial… More | ||
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | PAR-25-153 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as… More | ||
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | PAR-25-095 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary… More | ||
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | PAR-25-096 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary… More | ||
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | PAR-24-306 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor… More |